Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice

Cancer Letters

Volumn 146, Issue 1, 1999, Pages 15-23

  Shah, Neha ^a,b   Antony, Thomas ^a   Haddad, Salim ^a   Amenta, Peter ^a,c   Shirahata, Akira ^d   Thomas, T J ^a,c   Thomas, Thresia ^a,c,e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d JOSAI UNIVERSITY   (Japan)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Breast cancer; FVB NTgN (MMTVneu) transgenic mice; Polyamine analogs

Indexed keywords

NORSPERMINE; POLYAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VOLUME;

ACETYLTRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOGENIC POLYAMINES; FEMALE; GENES, ERBB-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; POLYAMINES; SPERMINE;

EID: 0032875359     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00215-3     Document Type: Article

References (39)

1. Porter C.W., Sufrin J.R. Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy: a review. Anticancer Res. 6:1986;525-542.
2. Porter C.W., McManis J., Casero R.A., Bergeron R.J. Relative abilities of bis(ethyl) derivatives of putrescine, spermidine, and spermine to regulate polyamine biosynthesis and inhibit L1210 leukemia cell growth. Cancer Res. 47:1987;2821-2825.
3. Pegg A.E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res. 48:1988;759-774.
4. Thomas T., Faaland C.A., Adhikarakunnathu S., Thomas T.J. Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF7 breast cancer cells. Breast Cancer Res. Treat. 39:1996;293-306.
5. Thomas T., Kiang D.T., Janne O.A., Thomas T.J. Variations in amplification and expression of the ornithine decarboxylase gene in human breast cancer cells. Breast Cancer Res. Treat. 19:1991;257-267.
6. Porter C.W., Herrera-Ornelas L., Petrelli N.F., Mittelman A. Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer (Phila). 60:1987;1275-1281.
7. Tabib A., Bachrach U. Polyamines induce malignant transformation in cultured NIH 3T3 fibroblasts. Int. J. Biochem. Cell Biol. 30:1998;135-146.
8. Soler A.P., Gilliard G., Megosh L., George K., O'Brien T.G. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res. 58:1998;1654-1659.
9. Mamont P.S., Duchesne M.C., Grove J., Bey P. Antiproliferative properties of DL-α-difluoromethylornithine in cultured cells. A consequence of irreversible inhibition of ornithine decarboxylase. Biochem. Biophys. Res. Commun. 81:1978;58-66.
10. Luk G.D., Abeloff M.D., Griffin C.A., Baylin S.B. Successful treatment with DL-α-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res. 43:1983;4239-4243.
11. Pegg A.E., McCann P.P. Polyamine metabolism and function. Am. J. Physiol. 243:1982;C212-C221.
12. Seiler N., Sarhan S., Grauffel C., Jones R., Knodgen B., Moulinoux J.P. Endogenous and exogenous polyamines in support of tumor growth. Cancer Res. 50:1990;5077-5083.
13. 8-spermidine derivatives in cultured L1210 leukemia cells. Cancer Res. 45:1985;2050-2057.
14. Bernacki R.J., Bergeron R.J., Porter C.W. Antitumor activity of N,N′-bis(ethyl)spermine homologues against human MALME3 melanoma xenografts. Cancer Res. 52:1992;2424-2430.
15. 11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Cancer Res. 55:1993;581-586.
16. Chang B.K., Bergeron R.J., Porter C.W., Liang Y. Antitumor effects of N-alkylated polyamine analogues in human pancreatic adenocarcinoma models. Cancer Chemother. Pharmacol. 30:1992;179-182.
17. Igarashi K., Koga K., He Y., Shimogori T., Ekimoto H., Kashiwagi K., Shirahata A. Inhibition of the growth of various human and mouse tumor cells by 1,15-bis(ethylamino)4,8,12-triazapentadecane. Cancer Res. 55:1995;2615-2619.
18. Zagaja G.P., Shrivastav M., Fleig M.J., Marton L.J., Rinker-Schaeffer C.W., Dolan M.E. Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother. Pharmacol. 41:1998;505-512.
19. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel verbB-related gene in a human mammary carcinoma. Science. 229:1985;974-976.
20. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 235:1987;177-182.
21. Iglehart D., Kraus M.H., Langton B.C., Huper G., Kerns B.J., Marks J.R. Increased erbB2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 50:1990;6701-6707.
22. Perren T.J. cerbB2 oncogene as a prognostic marker in breast cancer. Br. J. Cancer. 63:1991;328-332.
23. Manni A., Wecher R., Verderame M.F., Mauger D. Cooperativity between the polyamine pathway and HER2neu in transformation of human mammary epithelial cells in culture: role of the MAPK pathway. Int. J. Cancer. 76:1998;563-570.
24. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89:1992;10578-10582.
25. Jolicoeur P., Bouchard L., Guimond A., Ste-Marie M., Hanna Z., Dievart A. Use of mouse mammary tumor virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumor development. Biochem. Soc. Symp. 63:1998;159-165.
26. Matsui I., Pegg A.E. Effect of thioacetamide, growth hormone or partial hepatectomy on spermidine acetylase activity of rat liver cytosol, Biochem. Biophys. Res. Commun. 92:1980;1009-1015.
27. 12-bis(ethyl)spermine in human cell lines representing the major forms of lung cancer. Cancer Res. 52:1992;5359-5363.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:1976;248-254.
29. 12-bis(ethyl)spermine. Cancer Res. 53:1993;2071-2075.
30. 8-bis(ethyl)spermidine. Cancer Res. 47:1987;3964.
31. Jeffers L., Church D., Basu H., Marton L., Wilding G. Effects of the polyamine analogues BE4444, BE373, and BE333 on the proliferation of three prostate cancer cell lines. Cancer Chemother. Pharmacol. 40:1997;172-179.
32. 12-bis (ethyl)spermine and related compounds on growth and polyamine acetylation, content, and excretion in human colon tumor cells. J. Biol. Chem. 264:1989;11744-11749.
33. Basu H.S., Feuerstein B.G., Deen D.F., Lubich W.P., Bergeron R.J., Samejima K., Marton L.J. Correlation between the effects of polyamine analogues on DNA conformation and cell growth. Cancer Res. 49:1989;5591-5597.
34. 1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res. 51:1991;3715-3720.
35. Chang B.K., Bergeron R.J., Porter C.W., Vinson J.R.T., Liang Y., Libby P.R. Regulatory and antiproliferative effects of N-alkylated polyamine analogues in human and hamster pancreatic adenocarcinoma cell lines. Cancer Chemother. Pharmacol. 30:1992;183-188.
36. 12-bis(ethyl)spermine, on polyamine metabolism and cell growth in human melanoma cell lines and melanocytes. Anticancer Res. 12:1992;1083-1090.
37. 1-acetyltransferase activity by novel spermine analogs. Mol. Pharmacol. 1997. 52:1997;69-74.
38. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal foundation award lecture. Clin. Cancer Res. 4:1998;1079-1086.
39. Love R.R., Jacoby R., Newton M.A., Tutsch K.D., Simon K., Pomplun M., Verma A.R. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 7:1998;989-992.